AstraZeneca PLC Second quarter and half year results 2011
- Details
- Category: AstraZeneca
AstraZeneca's revenue in the second quarter was down 2 percent at CER, but was up 3 percent on an actual basis as a result of the positive impact of exchange rate movements. This global revenue performance reflects government price interventions as well as the impact of more than $0.5 billion in revenue lost to generic competition, with the impact from generics in the US and Rest of World broadly similar.
"Roche Continents" at the Salzburg Festival celebrates its five-year anniversary
- Details
- Category: Roche
Roche and the Salzburg Festival are celebrating the fifth- anniversary of their collaboration this year. Once again, as in the past years of cooperation, students of the sciences, art and music of 34 different nationalities will come together in Salzburg
Merck Total Revenues Increase by 16% to EUR 2.6 Billion
- Details
- Category: Merck Group
Total revenues of the Merck Group increased 16% to € 2,555 million in the second quarter from € 2,208 million in the year-ago quarter, boosted by the July 2010 acquisition of the Millipore Corporation.
Lilly Global Giving Puts Power of Philanthropy in Employees' Hands
- Details
- Category: Eli Lilly and Company
For the first time, Eli Lilly and Company (NYSE: LLY) employees worldwide can donate to more than 800 grassroots projects across the globe and have their donations matched by the Eli Lilly and Company Foundation - doubling the value and impact of each employee's charitable contribution.
Roche to provide HIV/AIDS tests for Early Infant Diagnosis in South Africa
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) has been awarded an exclusive contract by the National Health Laboratory Services (NHLS) in South Africa for the support of the Early Infant Diagnosis (EID) Programme.
New Senior Executives appointed at Sanofi
- Details
- Category: Sanofi
Sanofi (EURONEXT : SAN ; NYSE : SNY) announced the appointment of Greg Irace, currently President and CEO of Sanofi's US operations, to the newly created role of Senior Vice President, Global Services.
Bristol-Myers Squibb to Acquire Amira Pharmaceuticals
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) and Amira Pharmaceuticals, Inc., announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire privately held Amira Pharmaceuticals, a small-molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases.
More Pharma News ...
- FDA approves new medicine BRILINTA (ticagrelor) for use in the US
- Pfizer To Acquire Icagen
- FDA Advisory Committee Makes Recommendation on Investigational Compound Dapagliflozin
- Novartis delivers strong financial results and four major approvals
- Abbott Confirms Long-Term Commitment to HIV Care
- Novartis begins shipment of Fluvirin® seasonal influenza vaccine to US customers
- XGEVA® (Denosumab) Granted Marketing Authorization in the European Union